应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01801 信达生物
未开盘 02-07 16:08:09
36.250
+0.450
+1.26%
最高
37.200
最低
35.550
成交量
1,195万
今开
36.000
昨收
35.800
日振幅
4.61%
总市值
593.78亿
流通市值
593.78亿
总股本
16.38亿
成交额
4.36亿
换手率
0.73%
流通股本
16.38亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
信达生物2024年收入超82亿;复宏汉霖:H药欧盟获批,HLX15达成出海合作
Ofweek光电信息网 · 02-07 15:25
信达生物2024年收入超82亿;复宏汉霖:H药欧盟获批,HLX15达成出海合作
信达生物(01801.HK)升逾3% 野村指去年销售胜预期
阿斯达克财经 · 02-07 11:36
信达生物(01801.HK)升逾3% 野村指去年销售胜预期
信达生物现涨超3% 公司去年商业化成绩亮眼机构看好其后续发展
新浪港股 · 02-07 11:20
信达生物现涨超3% 公司去年商业化成绩亮眼机构看好其后续发展
2024年产品收入超82亿元 信达生物股价收盘上涨8.32%
新京报 · 02-07 11:14
2024年产品收入超82亿元 信达生物股价收盘上涨8.32%
【港股通】信达生物(01801)升逾3.2% 去年产品收入增长超40% 机构料其今年商业化成绩将更上一层楼
金吾财讯 · 02-07 10:43
【港股通】信达生物(01801)升逾3.2% 去年产品收入增长超40% 机构料其今年商业化成绩将更上一层楼
港股异动 | 信达生物(01801)续涨超3% 公司去年商业化成绩亮眼 25年将有6款新产品陆续上市销售
智通财经 · 02-07 10:17
港股异动 | 信达生物(01801)续涨超3% 公司去年商业化成绩亮眼 25年将有6款新产品陆续上市销售
【港股通】信达生物(01801)2024年全年总产品收入同比保持40%以上增长
金吾财讯 · 02-07 09:03
【港股通】信达生物(01801)2024年全年总产品收入同比保持40%以上增长
智通港股早知道 | 央行等六部门拟规范供应链金融业务 欧盟建议对进口网购产品征收手续费
智通财经 · 02-07 07:32
智通港股早知道 | 央行等六部门拟规范供应链金融业务 欧盟建议对进口网购产品征收手续费
全年产品收入增速超40%!信达生物(1801.HK)踩足油门冲向“200亿”新目标
格隆汇 · 02-06
全年产品收入增速超40%!信达生物(1801.HK)踩足油门冲向“200亿”新目标
信达生物2024年总产品收入超82亿元
北京商报 · 02-06
信达生物2024年总产品收入超82亿元
复宏汉霖PD-1抑制剂获欧盟批准一线治疗肺癌,信达生物信迪利单抗联合疗法拟纳入优先审评,德曲妥珠单抗补充申请获FDA批准
医药经济报 · 02-06
复宏汉霖PD-1抑制剂获欧盟批准一线治疗肺癌,信达生物信迪利单抗联合疗法拟纳入优先审评,德曲妥珠单抗补充申请获FDA批准
信达生物(01801.HK)去年总产品收入逾82亿人币 按年增逾4成
阿斯达克财经 · 02-06
信达生物(01801.HK)去年总产品收入逾82亿人币 按年增逾4成
信达生物(01801)2024年总产品收入超82亿元,同比保持40%以上的强劲增长
智通财经 · 02-06
信达生物(01801)2024年总产品收入超82亿元,同比保持40%以上的强劲增长
国联证券:行业结构性分化或进一步加剧 创新药械及国际化布局领先的企业有望持续领跑
智通财经 · 02-06
国联证券:行业结构性分化或进一步加剧 创新药械及国际化布局领先的企业有望持续领跑
信达生物现涨超6% 公司在IO和ADC领域布局多项技术和多款创新产品
新浪港股 · 02-06
信达生物现涨超6% 公司在IO和ADC领域布局多项技术和多款创新产品
异动解读 | 信达生物(01801)盘中大涨5.45% 公司提出"IO+ADC"发展策略 2027年将实现营收200亿元
异动解读 · 02-06
异动解读 | 信达生物(01801)盘中大涨5.45% 公司提出"IO+ADC"发展策略 2027年将实现营收200亿元
信达生物盘中异动 早盘股价大涨5.14%
市场透视 · 02-06
信达生物盘中异动 早盘股价大涨5.14%
港股异动 | 信达生物(01801)现涨近5% 公司在IO和ADC领域布局多项技术和多款创新产品
智通财经 · 02-06
港股异动 | 信达生物(01801)现涨近5% 公司在IO和ADC领域布局多项技术和多款创新产品
【券商金股】券商指港股上行趋势确定性仍强 2月港股券商金股出炉(附名单)
金吾财讯 · 02-05
【券商金股】券商指港股上行趋势确定性仍强 2月港股券商金股出炉(附名单)
信达生物(01801.HK)2月4日收盘上涨1.22%,成交5885.96万港元
金融界 · 02-04
信达生物(01801.HK)2月4日收盘上涨1.22%,成交5885.96万港元
加载更多
公司概况
公司名称:
信达生物
所属市场:
SEHK
上市日期:
--
主营业务:
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格:
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":36.25,"timestamp":1738915689027,"preClose":35.8,"halted":0,"volume":11951937,"delay":0,"floatShares":1638000000,"shares":1638000000,"eps":-0.7028413445253768,"marketStatus":"未开盘","change":0.45,"latestTime":"02-07 16:08:09","open":36,"high":37.2,"low":35.55,"amount":436467036,"amplitude":0.046089,"askPrice":36.25,"askSize":393500,"bidPrice":36.2,"bidSize":25000,"shortable":3,"etf":0,"ttmEps":-0.8522435586803258,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1739151000000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":35.8,"openAndCloseTimeList":[[1738891800000,1738900800000],[1738904400000,1738915200000]],"volumeRatio":1.8123072890314469,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5177,"impliedVolPercentile":0.3115},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2509530793","title":"信达生物2024年收入超82亿;复宏汉霖:H药欧盟获批,HLX15达成出海合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2509530793","media":"Ofweek光电信息网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509530793?lang=zh_cn&edition=full","pubTime":"2025-02-07 15:25","pubTimestamp":1738913100,"startTime":"0","endTime":"0","summary":"信达生物展示肌肉。2月6日,信达生物公告表示,2024年收入超82亿,同比增长超40%。第四季度,公司收入超20亿元。复宏汉霖持续收获出海成果。2月5日,复宏汉霖抗PD-1单抗 H药汉斯状正式获得欧盟委员会批准,成为首个且唯一在欧盟获批上市用于广泛期小细胞肺癌治疗的抗PD-1单抗。2月6日,复宏汉霖宣布,与Dr. Reddy’s Laboratories SA就达雷妥尤单抗生物类似药HLX15签署授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207153630987d5105&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207153630987d5105&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","BK1589","01801","LU2328871848.SGD","LU2488822045.USD","02696","BK1161"],"gpt_icon":0},{"id":"2509754731","title":"信达生物(01801.HK)升逾3% 野村指去年销售胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2509754731","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509754731?lang=zh_cn&edition=full","pubTime":"2025-02-07 11:36","pubTimestamp":1738899360,"startTime":"0","endTime":"0","summary":"信达生物今日高开0.6%后早段升幅扩大,最高见37.2元。集团上日收市后公布去年末季及全年销售更新。野村回应称,信达生物去年销售胜该行及市场预期。管理层指去年产品销售按年升逾40%至82亿元人民币,高于该行及市场预期,归功于sintilimab增长稳定及新药销售快速加大。去年末季信达生物销售逾20亿元人民币,按年升25%,按季则跌13%。管理层重申至2027年国内产品销售目标200亿元人民币,受更丰富的产品组合支持。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415584/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1969619763.USD","BK1161","LU2488822045.USD","BK1583","BK1589","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2509512827","title":"信达生物现涨超3% 公司去年商业化成绩亮眼机构看好其后续发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2509512827","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509512827?lang=zh_cn&edition=full","pubTime":"2025-02-07 11:20","pubTimestamp":1738898400,"startTime":"0","endTime":"0","summary":" 信达生物早盘上涨3.07%,报36.90港元,成交额2.40亿港元。 中信建投证券发布研报称,公司2024年产品收入超82亿元,同比保持40%以上强劲增长,商业化成绩亮眼,销售额符合市场预期。在此基础上,公司2025年将有6款新产品陆续上市销售,同时随着托来西单抗成功进入医保目录,该行认为公司2025 年的商业化成绩将更上一层楼。整体看,公司商业化成绩持续亮眼,并稳步向2027年国内200亿营收目标迈进,看好公司后续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-07/doc-ineirmwm0268705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01801","LU1969619763.USD","LU2328871848.SGD","BK1583","LU2488822045.USD","BK1161","BK1589"],"gpt_icon":0},{"id":"2509950754","title":"2024年产品收入超82亿元 信达生物股价收盘上涨8.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509950754","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509950754?lang=zh_cn&edition=full","pubTime":"2025-02-07 11:14","pubTimestamp":1738898062,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯(记者丁爽)2月6日,信达生物在港交所发布公告称,2024年全年,公司取得总产品收入超82亿元,同比保持40%以上增长。其中,2024年第四季度,公司共取得总产品收入超20亿元,同比增长超25%。截至2月6日收盘,信达生物股价报35.8港元,涨8.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313275117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313275117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU2328871848.SGD","BK1589","BK1161","01801","LU2488822045.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2509954756","title":"【港股通】信达生物(01801)升逾3.2% 去年产品收入增长超40% 机构料其今年商业化成绩将更上一层楼","url":"https://stock-news.laohu8.com/highlight/detail?id=2509954756","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509954756?lang=zh_cn&edition=full","pubTime":"2025-02-07 10:43","pubTimestamp":1738896227,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物 早盘股价延续升势,并升至近1个月高位,截至发稿,报36.95港元,涨3.21%,成交额1.9亿港元。其中,2024年第四季度,本公司共取得总产品收入超人民币20亿元,同比增长超25%。中信建投表示,公司商业化成绩亮眼,销售额符合市场预期。在此基础上,公司2025年将有6款新产品陆续上市销售,同时随着托来西单抗成功进入医保目录,该行认为公司2025年的商业化成绩将更上一层楼。维持“买入”评级。予目标价至71.92 港元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952699","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","HSTECH","01801","BK1161","LU2488822045.USD","LU1969619763.USD","BK1589","HSCEI","YANG","LU2328871848.SGD"],"gpt_icon":1},{"id":"2509553637","title":"港股异动 | 信达生物(01801)续涨超3% 公司去年商业化成绩亮眼 25年将有6款新产品陆续上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2509553637","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509553637?lang=zh_cn&edition=full","pubTime":"2025-02-07 10:17","pubTimestamp":1738894663,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物续涨超3%,截至发稿,涨3.49%,报37.5港元,成交额1.6亿港元。中信建投证券发布研报称,公司2024年产品收入超82亿元,同比保持40%以上强劲增长,商业化成绩亮眼,销售额符合市场预期。在此基础上,公司2025年将有6款新产品陆续上市销售,同时随着托来西单抗成功进入医保目录,该行认为公司2025 年的商业化成绩将更上一层楼。整体看,公司商业化成绩持续亮眼,并稳步向2027年国内200亿营收目标迈进,看好公司后续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 信达生物(01801)续涨超3% 公司去年商业化成绩亮眼 25年将有6款新产品陆续上市销售","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","01801","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1583","BK1589"],"gpt_icon":0},{"id":"2509732257","title":"【港股通】信达生物(01801)2024年全年总产品收入同比保持40%以上增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2509732257","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509732257?lang=zh_cn&edition=full","pubTime":"2025-02-07 09:03","pubTimestamp":1738890207,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物(01801)公布,2024年全年及第四季度产品收入的最新消息。2024年全年,公司取得总产品收入超人民币82亿元,同比保持40%以上的强劲增长。其中,2024年第四季度,本公司共取得总产品收入超人民币20亿元,同比增长超25%。产品收入的快速增长主要得益于:1)公司已成为肿瘤治疗领域的领导品牌,达伯舒(信迪利单抗注射液)等主要产品保持强劲的增长势头;及2)愈发丰富的新产品组合快速成长,为收入的持续增长贡献新驱动力。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MTc2MjljY2IwYTgxMzM5MTU0OTIzNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MTc2MjljY2IwYTgxMzM5MTU0OTIzNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","LU2488822045.USD","BK1583","LU2328871848.SGD","YANG","01801","HSCEI","BK1161","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2509736339","title":"智通港股早知道 | 央行等六部门拟规范供应链金融业务 欧盟建议对进口网购产品征收手续费","url":"https://stock-news.laohu8.com/highlight/detail?id=2509736339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509736339?lang=zh_cn&edition=full","pubTime":"2025-02-07 07:32","pubTimestamp":1738884772,"startTime":"0","endTime":"0","summary":"意见稿提到,应收账款电子凭证付款期限原则上应在6个月以内,最长不超过1年。付款期限超过6个月的,商业银行应对账期合理性和行业结算惯例加强审查,审慎开展融资业务。欧盟委员会称,廉价、不安全的进口产品对遵守规则的欧盟卖家构成不公平竞争,而大量包裹的运输对环境和气候造成了负面影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","LU0797268264.HKD","LU0456827905.SGD","LU0708995583.HKD","LU0823397285.USD","BK1502","HSCEI","LU0211977185.USD","LU0634319403.HKD","YANG","BK1575","LU1770036033.HKD","LU1808992512.USD","01801","LU0348827113.USD","LU2488822045.USD","LU0823426308.USD","LU0348735423.USD","LU0320764599.SGD","02696","01274","81810","XIACY","LU0561508036.HKD","BK1607","LU1282648689.USD","IE0034224299.USD","LU1303224171.USD","LU0531971595.HKD","LU0314109678.HKD","LU0359201612.USD","LU0348814723.USD","LU0611395673.USD","01810","BK1193","BK1521","LU2778985437.USD","BK1144","BK1583","LU0345775950.USD","LU0345776255.USD","BK1506","LU0051755006.USD","HSTECH","BK1523","LU0164880469.USD","LU1328277881.USD","LU0307460666.USD","LU0164865239.USD"],"gpt_icon":1},{"id":"2509225998","title":"全年产品收入增速超40%!信达生物(1801.HK)踩足油门冲向“200亿”新目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2509225998","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509225998?lang=zh_cn&edition=full","pubTime":"2025-02-06 18:44","pubTimestamp":1738838643,"startTime":"0","endTime":"0","summary":"至2027年,国内产品收入要突破200亿元大关。","market":"hk","thumbnail":"https://img2.gelonghui.com/e55e7-8b8c6f6e-468e-488e-b76f-ca5a2a445a1e.jpg?guru_height=1080&guru_width=1920","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/e55e7-8b8c6f6e-468e-488e-b76f-ca5a2a445a1e.jpg?guru_height=1080&guru_width=1920"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1701028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU2328871848.SGD","01801","LU2488822045.USD","LU1969619763.USD","BK1589","BK1583","BK1161"],"gpt_icon":0},{"id":"2509289142","title":"信达生物2024年总产品收入超82亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509289142","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509289142?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:57","pubTimestamp":1738835856,"startTime":"0","endTime":"0","summary":"北京商报讯(记者王寅浩)2月6日,信达生物发布公告称,2024年全年公司取得总产品收入超82亿元,同比保持40%以上的增长。其中,2024年第四季度,公司共取得总产品收入超20亿元,同比增长超25%。信达生物方面表示,产品收入的快速增长主要得益于:达伯舒?(信迪利单抗注射液)等主要产品保持强劲的增长势头;愈发丰富的新产品组合快速成长,为收入的持续增长贡献新驱动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502063312411980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502063312411980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","01801","BK1161","BK1589","LU2328871848.SGD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2509407182","title":"复宏汉霖PD-1抑制剂获欧盟批准一线治疗肺癌,信达生物信迪利单抗联合疗法拟纳入优先审评,德曲妥珠单抗补充申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407182","media":"医药经济报","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509407182?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:53","pubTimestamp":1738835599,"startTime":"0","endTime":"0","summary":"与此同时,复宏汉霖同步在全球开展10余项以斯鲁利单抗为核心的免疫联合疗法临床研究。公开资料显示,这是信达生物在研的抗CTLA-4单抗IBI310与抗PD-1单抗信迪利单抗联合疗法,该联合疗法此前已经被CDE纳入突破性治疗品种。信迪利单抗是一种抗PD-1单抗,能够阻断导致肿瘤免疫耐受的PD-1/L1通路,重新启动淋巴细胞的抗肿瘤活性,从而达到治疗肿瘤的目的。本次IBI310联合信迪利单抗拟纳入优先审评,意味着这款联合疗法有望加速获批,惠及患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206180205abc48936&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206180205abc48936&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01801","LU1969619763.USD","BK1589","LU2328871848.SGD","02696","LU2488822045.USD"],"gpt_icon":0},{"id":"2509247288","title":"信达生物(01801.HK)去年总产品收入逾82亿人币 按年增逾4成","url":"https://stock-news.laohu8.com/highlight/detail?id=2509247288","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509247288?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:35","pubTimestamp":1738834500,"startTime":"0","endTime":"0","summary":"信达生物公布,去年总产品收入超过82亿元人民币(下同),按年保持40%以上的强劲增长。其中,去年第四季度共取得总产品收入逾20亿元,按年增长逾25%。今年将新增三款肿瘤药物上市,包括肺癌创新靶向药物达伯乐、奥壹新和血液瘤产品捷帕力。另外,信必乐纳入新版国家医保目录并已于2025年1月1日生效。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415342/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","LU1969619763.USD","01801","BK1583","LU2328871848.SGD","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2509247316","title":"信达生物(01801)2024年总产品收入超82亿元,同比保持40%以上的强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2509247316","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509247316?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:31","pubTimestamp":1738834291,"startTime":"0","endTime":"0","summary":"2025年将是公司商业化快速发展的一年,公司将在持续发展现有产品的同时,做好新增六款创新药的上市销售和新进医保目录产品的销售。其中,信必乐 纳入新版国家医保目录并已于2025年1月1 日生效。2024年令人满意的销售成绩和丰厚的高潜后期管线,增强了公司在2027年实现人民币200亿元国内产品收入目标的信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"信达生物(01801)2024年总产品收入超82亿元,同比保持40%以上的强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1589","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","BK1583","01801"],"gpt_icon":0},{"id":"2509195072","title":"国联证券:行业结构性分化或进一步加剧 创新药械及国际化布局领先的企业有望持续领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2509195072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509195072?lang=zh_cn&edition=full","pubTime":"2025-02-06 14:11","pubTimestamp":1738822309,"startTime":"0","endTime":"0","summary":"未来行业结构性分化或进一步加剧,创新药械及国际化布局领先的企业有望持续领跑。各细分行业表现不同,净利润增速显著分化其余子板块中,生物制品领域三生国健、神州细胞等4家企业净利润翻倍,但超四成企业(14家)净利润下滑≥50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","601456","01801","399265","LU1969619763.USD","BK1589","BK1564","BK0276","LU2328871848.SGD","01456","BK1147","LU2488822045.USD"],"gpt_icon":0},{"id":"2509291673","title":"信达生物现涨超6% 公司在IO和ADC领域布局多项技术和多款创新产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2509291673","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509291673?lang=zh_cn&edition=full","pubTime":"2025-02-06 11:18","pubTimestamp":1738811880,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 信达生物(01801)早盘上涨6.35%,现报35.15港元,成交额1.98亿港元。\n 信达生物在43届JPM大会上发表演讲,表示2027年将有超过20款商业化产品上市,同时国内营收实现超200亿元目标。在此基础上,公司提出“IO+ADC”的肿瘤发展策略,在IO和ADC领域布局多项技术和多款创新产品。值得注意的是,信达生物此前回应生物药集采称,2027年200亿业绩目标已包含集采影响。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiphxh1179659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK4080","LU2488822045.USD","01801","BK4563","LU2328871848.SGD","BK1161","BK1589","BK4231","BK4179","IO","LU1969619763.USD","ADC"],"gpt_icon":0},{"id":"1138416428","title":"异动解读 | 信达生物(01801)盘中大涨5.45% 公司提出\"IO+ADC\"发展策略 2027年将实现营收200亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138416428","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138416428?lang=zh_cn&edition=full","pubTime":"2025-02-06 10:52","pubTimestamp":1738810355,"startTime":"0","endTime":"0","summary":"生物制药公司信达生物(01801)今日盘中大涨5.45%,引起了市场的广泛关注。\n\n消息面上,信达生物在一个投资者大会上阐述了公司的发展战略。首先,该公司预计在2027年将有超过20种创新药物产品实现商业化上市,届时国内营收目标有望突破200亿元。\n\n在细分领域方面,信达生物提出了\"IO+ADC\"的肿瘤发展策略,即在免疫肿瘤(IO)和抗体偶联药物(ADC)等领域大力布局,拥有多项前沿技术和多款创新产品处于研发中。分析人士认为,这显示了该公司拥有较强的创新实力,产品管线具备良好前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"gpt_icon":0},{"id":"2509299831","title":"信达生物盘中异动 早盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509299831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509299831?lang=zh_cn&edition=full","pubTime":"2025-02-06 10:49","pubTimestamp":1738810197,"startTime":"0","endTime":"0","summary":"2025年02月06日早盘10时49分,信达生物股票出现波动,股价快速上涨5.14%。截至发稿,该股报34.750港元/股,成交量377.374万股,换手率0.23%,振幅6.20%。信达生物股票所在的药品行业中,整体涨幅为0.26%。其相关个股中,联邦制药、海王英特龙、信达生物涨幅较大,振幅较大的相关个股有顺腾国际控股、联邦制药、信达生物,振幅分别为22.58%、9.69%、6.05%。信达生物公司简介:信达生物制药是一家从事药物研发、生产及销售的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502061049579619962c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502061049579619962c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","01801","BK1161"],"gpt_icon":0},{"id":"2509129308","title":"港股异动 | 信达生物(01801)现涨近5% 公司在IO和ADC领域布局多项技术和多款创新产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2509129308","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509129308?lang=zh_cn&edition=full","pubTime":"2025-02-06 10:25","pubTimestamp":1738808736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物现涨近5%,截至发稿,涨4.24%,报34.45港元,成交额9308.48万港元。消息面上,信达生物在43届JPM大会上发表演讲,表示2027年将有超过20款商业化产品上市,同时国内营收实现超200亿元目标。在此基础上,公司提出“IO+ADC”的肿瘤发展策略,在IO和ADC领域布局多项技术和多款创新产品。值得注意的是,信达生物此前回应生物药集采称,2027年200亿业绩目标已包含集采影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4179","LU2488822045.USD","IO","BK4563","01801","BK4231","BK1161","LU1969619763.USD","BK4080","ADC","LU2328871848.SGD","BK1583","BK1589"],"gpt_icon":0},{"id":"2509479149","title":"【券商金股】券商指港股上行趋势确定性仍强 2月港股券商金股出炉(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509479149","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509479149?lang=zh_cn&edition=full","pubTime":"2025-02-05 16:19","pubTimestamp":1738743571,"startTime":"0","endTime":"0","summary":"至于上证指数月跌幅3%,创业板指跌3.6%。浙商证券表示,整体来看,港股市场虽然资金面和情绪面未有明显改善,但可以看到基本面表现有亮点,且政策面仍在不断加码,因此该行对于港股市场的短期观点由谨慎转为谨慎乐观。在板块配置方面,浙商证券看好行业相对景气且受益于政策利好的汽车、电子、家电、科技等;业绩和股价走势稳健且受益于政策利好的低估值国央企红利板块;基本面相对独立且受益于降息周期的香港本地银行及公用事业股。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952566","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","00285","LU0320764599.SGD","01801","02268","LU0214875030.USD","00823","LU0052750758.USD","LU0605514214.HKD","SG9999001689.USD","01193","01818","LU0708995153.HKD","80700","LU1048484197.HKD","LU0326950275.SGD","LU0577902538.SGD","HSTECH","09896","09636","09961","LU0293314216.USD","HK0000320223.HKD","BK1539","IE00B8L5B284.USD","BK1587","06110","01836","03121","BK1141","LU1733274390.USD","IE00B3M56506.USD","HSCEI","LU1303224171.USD","LU0054237671.USD","LU1196710351.USD","02382","09926","03898","LU2125910500.SGD","SG9999018865.SGD","YANG","HTCD.SI","02285","LU2097828805.USD","LU0516423091.SGD"],"gpt_icon":1},{"id":"2508438456","title":"信达生物(01801.HK)2月4日收盘上涨1.22%,成交5885.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508438456","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508438456?lang=zh_cn&edition=full","pubTime":"2025-02-04 16:41","pubTimestamp":1738658492,"startTime":"0","endTime":"0","summary":"2月4日,截至港股收盘,恒生指数上涨2.83%,报20789.96点。信达生物收报33.15港元/股,上涨1.22%,成交量177.84万股,成交额5885.96万港元,振幅5.95%。最近一个月来,信达生物累计跌幅7.62%,今年来累计跌幅10.52%,跑输恒生指数0.78%的涨幅。至2023年10月,信达生物患者援助项目已惠及17余万普通患者,药物捐赠总价值34亿元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/04164147947449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","01801","LU2488822045.USD","BK1589","LU1969619763.USD","BK1583","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0968},{"period":"1month","weight":0.0677},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.1297},{"period":"1year","weight":0.0447},{"period":"ytd","weight":-0.0096}],"compareEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":0.0961},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.2366},{"period":"1year","weight":0.331},{"period":"ytd","weight":0.0535}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.101115},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078824},{"month":12,"riseRate":0.428571,"avgChangeRate":0.054557}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}